{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T02:51:24Z","timestamp":1774839084440,"version":"3.50.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cjca.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:35:55Z","timestamp":1718339755000},"page":"1503-1523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient With Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"40","author":[{"given":"Andrew M.","family":"Crean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Christian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Garceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Giraldeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobak","family":"Heydari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Laksman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Mital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colette M.","family":"Seifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-0258","authenticated-orcid":false,"given":"Rafik","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2024.06.007_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.06.007_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.06.007_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002460","article-title":"Evaluating the clinical validity of hypertrophic cardiomyopathy genes","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib5","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","article-title":"Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the International Sarcomeric Human Cardiomyopathy Registry","volume":"13","author":"Canepa","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2024.06.007_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2024.06.007_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A\u00a0novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O\u2019Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.06.007_bib10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","article-title":"Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)","volume":"4","author":"Norrish","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A\u00a0validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jamacardio.2023.1042","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"8","author":"Lampert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib13","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.06.007_bib14","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib15","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.06.007_bib16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.cjca.2024.01.011","article-title":"Emerging themes in genetics of hypertrophic cardiomyopathy: current status and clinical application","volume":"40","author":"Garcia-Hernandez","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.cjca.2024.06.007_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001560","article-title":"Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity","volume":"8","author":"de Feria","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.cjca.2024.06.007_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12872-021-01927-5","article-title":"Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients","volume":"21","author":"Hathaway","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cjca.2024.06.007_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001815","article-title":"Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"9","author":"Christian","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.cjca.2024.06.007_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1161\/CIRCGENETICS.110.958835","article-title":"Sarcomere protein gene mutations in patients with apical hypertrophic cardiomyopathy","volume":"4","author":"Gruner","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2024.06.007_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41436-019-0666-z","article-title":"Diagnostic gene sequencing panels: from design to report-a technical standard of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"Bean","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/europace\/euac030","article-title":"expert consensus statement on the state of genetic testing for cardiac diseases","volume":"24","author":"Wilde","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2024.06.007_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.hrthm.2022.03.1225","article-title":"expert consensus statement on the state of genetic testing for cardiac diseases","volume":"19","author":"Wilde","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2024.06.007_bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib28","article-title":"Incremental prognostic utility of left ventricular global longitudinal strain in hypertrophic obstructive cardiomyopathy patients and preserved left ventricular ejection fraction","volume":"6","author":"Tower-Rader","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2024.06.007_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ejechocard\/jer318","article-title":"Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy","volume":"13","author":"Saito","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.06.007_bib30","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2023.07.012","article-title":"Improved diagnostic criteria for apical hypertrophic cardiomyopathy","volume":"17","author":"Hughes","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.06.007_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjci\/jew313","article-title":"Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study","volume":"19","author":"Reant","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.06.007_bib33","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.107.698985","article-title":"Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization","volume":"116","author":"Geske","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib34","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.jacc.2013.02.079","article-title":"Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy","volume":"61","author":"Feiner","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib35","doi-asserted-by":"crossref","first-page":"G61","DOI":"10.1530\/ERP-20-0042","article-title":"Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography","volume":"8","author":"Turvey","year":"2021","journal-title":"Echo Res Pract"},{"key":"10.1016\/j.cjca.2024.06.007_bib36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.echo.2024.02.010","article-title":"Obstruction in hypertrophic cardiomyopathy: many faces","volume":"37","author":"Abbasi","year":"2024","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2024.06.007_bib37","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.amjcard.2019.01.041","article-title":"Role of preoperative cardiovascular magnetic resonance in planning ventricular septal myectomy in patients with obstructive hypertrophic cardiomyopathy","volume":"123","author":"Spirito","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib38","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/rct.0b013e31803151fd","article-title":"MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy","volume":"31","author":"Amano","year":"2007","journal-title":"J\u00a0Comput Assist Tomogr"},{"key":"10.1016\/j.cjca.2024.06.007_bib39","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/hrt.2003.014969","article-title":"Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography","volume":"90","author":"Moon","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2024.06.007_bib40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ehjci\/jew045","article-title":"CMR assessment of the left ventricle apical morphology in subjects with unexplainable giant T-wave inversion and without apical wall thickness > \/\u00a0= 15 mm","volume":"18","author":"Wu","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.06.007_bib41","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jcmg.2019.09.020","article-title":"The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications","volume":"13","author":"Rowin","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2024.06.007_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2010.03.020","article-title":"Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy","volume":"106","author":"Olivotto","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.athoracsur.2005.01.064","article-title":"Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair","volume":"80","author":"Balaram","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cjca.2024.06.007_bib45","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000000682","article-title":"Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American Heart Association","volume":"140","author":"Lipshultz","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2021.03.056","article-title":"Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"332","author":"Papanastasiou","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ehjqcco\/qcac008","article-title":"Implications of structural right ventricular involvement in patients with hypertrophic cardiomyopathy","volume":"9","author":"Zhang","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.cjca.2024.06.007_bib48","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.hrthm.2021.12.017","article-title":"Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: an international multicenter study","volume":"19","author":"Rowin","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2024.06.007_bib50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cjco.2022.01.001","article-title":"Arrhythmia monitoring for risk stratification in hypertrophic cardiomyopathy","volume":"4","author":"Du","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2024.06.007_bib51","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004052","article-title":"Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation","volume":"10","author":"Debonnaire","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2024.06.007_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.hrthm.2020.09.018","article-title":"Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a review","volume":"18","author":"Nasser","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2024.06.007_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib55","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib56","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib57","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1161\/STROKEAHA.119.026048","article-title":"Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2024.06.007_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2017.08.010","article-title":"Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"248","author":"Dominguez","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jce.14880","article-title":"Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: long-term results and clinical outcomes","volume":"32","author":"Castagno","year":"2021","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib61","article-title":"Utilization and complications of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"9","author":"Rozen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2024.06.007_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101524","article-title":"Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"48","author":"Faraz","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib63","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jtcvs.2017.08.063","article-title":"Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy","volume":"155","author":"Bogachev-Prokophiev","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cjca.2024.06.007_bib64","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.hrthm.2023.08.028","article-title":"Atrioventricular nodal ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"20","author":"Butcher","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2024.06.007_bib65","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacc.2008.11.069","volume":"54","author":"Maron","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib67","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.06.007_bib68","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib69","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199703133361107","article-title":"The management of hypertrophic cardiomyopathy","volume":"336","author":"Spirito","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s003950050126","article-title":"Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment","volume":"94","author":"Choudhury","year":"1999","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/hrt.42.1.35","article-title":"Treatment of hypertrophic obstructive cardiomyopathy with verapamil","volume":"42","author":"Kaltenbach","year":"1979","journal-title":"Br Heart J"},{"key":"10.1016\/j.cjca.2024.06.007_bib72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM198210143071607","article-title":"Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide","volume":"307","author":"Pollick","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib73","series-title":"Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration","first-page":"1248","volume":"62","author":"Pollick","year":"1988"},{"key":"10.1016\/j.cjca.2024.06.007_bib74","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2024.06.007_bib75","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2024.06.007_bib76","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/10600280221117812","article-title":"Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"57","author":"Dalo","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2024.06.007_bib78","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jchf.2023.04.018","article-title":"Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: Heart Failure State-of-the-Art Review","volume":"11","author":"Ostrominski","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2024.06.007_bib79","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/jocs.14815","article-title":"Alcohol septal ablation: a useful tool in our arsenal against hypertrophic obstructive cardiomyopathy","volume":"35","author":"Savarimuthu","year":"2020","journal-title":"J\u00a0Card Surg"},{"key":"10.1016\/j.cjca.2024.06.007_bib80","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0038-1675213","article-title":"Results of ten-year follow-up of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy","volume":"27","author":"Kashtanov","year":"2018","journal-title":"Int J Angiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib81","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","article-title":"A\u00a0systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2024.06.007_bib82","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","article-title":"Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry","volume":"37","author":"Veselka","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.06.007_bib83","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib84","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cjco.2022.06.012","article-title":"Extended myectomy for hypertrophic cardiomyopathy: early outcomes from a nascent centre of excellence in Canada","volume":"4","author":"Crean","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2024.06.007_bib85","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/jcu.22989","article-title":"Clinical value of 2D speckle tracking imaging in evaluating the effect of percutaneous intramyocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"49","author":"Qian","year":"2021","journal-title":"J\u00a0Clin Ultrasound"},{"key":"10.1016\/j.cjca.2024.06.007_bib86","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jacc.2018.07.080","article-title":"Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy","volume":"72","author":"Liu","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib87","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jelectrocard.2020.06.013","article-title":"Electrocardiographic QRS voltage amplitude improvement by intramyocardial radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy and one year follow up","volume":"61","author":"Zuo","year":"2020","journal-title":"J\u00a0Electrocardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib88","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2017.06.071","article-title":"Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"243","author":"Pelliccia","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib89","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2024.06.007_bib90","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1365-2362.2010.02349.x","article-title":"Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study","volume":"40","author":"Nagueh","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cjca.2024.06.007_bib91","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2024.06.007_bib92","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib93","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.122.062699","article-title":"The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy","volume":"147","author":"Conway","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib94","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.06.007_bib95","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2024.06.007_bib96","first-page":"e783","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib97","first-page":"e273","volume":"132","author":"Maron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.06.007_bib98","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","article-title":"Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial","volume":"317","author":"Saberi","year":"2017","journal-title":"JAMA"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24004380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24004380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:28:25Z","timestamp":1725632905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X24004380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0828282X24004380"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2024.06.007","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient With Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}